Hepcidin: A new tool in the management of anaemia in patients with chronic kidney disease?

Nephrology Dialysis Transplantation

Volumn 23, Issue 8, 2008, Pages 2450-2453

  Swinkels, Dorine W ^a   Wetzels, Jack F M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chronic kidney disease; Erythropoietin; Hepcidin; Inflammation; Iron

Indexed keywords

HEMOGLOBIN; HEPCIDIN; IRON; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COST MINIMIZATION ANALYSIS; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; ERYTHROPOIESIS; HEALTH CARE COST; HEMOGLOBIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; IRON BLOOD LEVEL; IRON METABOLISM; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

ANEMIA; ANTIMICROBIAL CATIONIC PEPTIDES; BIOLOGICAL MARKERS; HEMATINICS; HUMANS; IRON; KIDNEY FAILURE, CHRONIC;

EID: 48749125607     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn267     Document Type: Review

References (38)

1. Pigeon C, Ilyin G, Courselaud B et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001; 276: 7811-7819
2. Park CH, Valore EV, Waring AJ et al. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001; 276: 7806-7810
3. Nemeth E, Tuttle MS, Powelson J et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306: 2090-2093
4. De Domenico I, Mc Vey Ward D, Kaplan J. Regulation of iron acquisition and storage: consequences for iron-linked disorders. Nat Rev Mol Cell Biol 2008; 9: 72-81
5. Dallalio G, Law E, Means RT Jr. Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrations. Blood 2006; 107: 2702-2704
6. Nicolas G, Viatte L, Bennoun M et al. Hepcidin, a new iron regulatory peptide. Blood Cells Mol Dis 2002; 29: 327-335
7. Nicolas G, Chauvet C, Viatte L et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia and inflammation. J Clin Invest 2002; 110: 1037-1044
8. Pak M, Lopez MA, Gabayan V et al. Suppression of hepcidin during anemia requires erythropoietic activity. Blood 2006; 108: 3730-3735
9. Ganz T. Hepcidin and its role in regulating systemic iron metabolism. Hematol Am Soc Hematol Educ Program 2006; 507: 29-35
10. Kemna EHJM, Tjalsma H, Willems JL et al. Hepcidin: from discovery to differential diagnosis. Haematologica 2008; 93: 90-97
11. Peyssonnaux C, Zinkernagel AS, Schuepbach RA et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 2007; 117: 1926-1932
12. Silvestri L, Pagani A, Camaschella C. Furin mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis. Blood 2008; 111: 924-931
13. Vokurka M, Krijt J, Sulc K et al. Hepcidin mRNA levels in mouse liver respond to inhibition of erythropoiesis. Physiol Res 2006; 55: 667-674
14. Kemna EHJM, Kartikasari AER, van Tits LHJ et al. Regulation of hepcidin: insights from biochemical analysis on human serum samples. Blood Cells Mol Dis 2007; 40: 339-346
15. Beguin Y. Soluble transferrin receptor for evaluation of erythropoiesis and iron status. Clin Chim Acta 2003; 329: 9-22
16. Tanno T, Bhanu NV, Oneal PA et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007; 13: 1096-1101
17. Kemna E, Pickkers P, Nemeth E et al. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood 2005; 106: 1864-1846
18. Brookes MJ, Sharma NK, Tselepis C et al. Serum pro-hepcidin: measuring active hepcidin or non-functional precursor? Gut 2005; 54: 169-170
19. Roe MA, Spinks C, Heath AL et al. Serum prohepcidin concentration: no association with iron absorption in healthy men, and no relationship with iron status in men carrying HFE mutations, hereditary haemochromatosis patients undergoing phlebotomy treatment, or pregnant woman. Br J Nutr 2007; 97: 544-549
20. Valore EV, Ganz T. Posttranslational processing of hepcidin in human hepatocytes is mediated by the prohormone convertase furin. Blood Cells Mol Dis 2008; 40: 132-138
21. Zoller H, McFarlane I, Theurl I et al. Primary iron overload with inappropriate hepcidin expression in V162del ferroportin disease. Hepatology 2005; 42: 466-472
22. Kulaksiz H, Gehrke SG, Janetzko A et al. Pro-hepcidin: expression and cell specific localisation in the liver and its regulation in hereditary haemochromatosis, chronic renal insufficiency, and renal anaemia. Gut 2004; 53: 735-743
23. Taes YE, Wuyts B, Boelaert JR et al. Prohepcidin accumulates in renal insufficiency. Clin Chem Lab Med 2004; 42: 387-389
24. Malyszko J, Malyszko JS, Pawlak K et al. Hepcidin, iron status, and renal function in chronic renal failure, kidney transplantation and hemodialysis. Am J Hematol 2006; 81: 832-837
25. Nemeth E, Valore EV, Territo M et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003; 101: 2461-2463
26. Kemna E, Tjalsma H, Laarakkers C et al. Novel urine hepcidin assay by mass spectrometry. Blood 2005; 106: 3268-3270
27. Kemna EHJM, Tjalsma H, Podust VN et al. Mass spectrometry-based hepcidin measurements in serum and urine: analytical aspects and clinical implications. Clin Chem 2007; 53: 620-628
28. Tomosugi N, Kawabata H, Wakatabe R et al. Detection of serum hepcidin in renal failure and inflammation by using ProteinChip system. Blood 2006; 108: 1381-1387
29. Murphy AT, Witcher DR, Luan P et al. Quantitation of hepcidin from human and mouse serum using liquid chromatography tandem mass spectrometry. Blood 2007; 110: 1048-1054
30. Murao N, Ishigai M, Yasuno H et al. Simple and sensitive quantification of bioactive peptides in biological matrices using liquid chromatography/ selected reaction monitoring mass spectrometry coupled with trichloroacetic acid clean-up. Rapid Commun Mass Spectrom 2007; 21: 4033-4038
31. Kulaksiz H, Theilig F, Bachmann S et al. The iron-regulatory peptide hormone hepcidin: expression and cellular localization in the mammalian kidney. J Endocrinol 2005; 184: 361-370
32. Kaysen GA, Müller HG, Ding J et al. Challenging the validity of the EPO index. Am J Kidney Dis 2006; 47: 166.e1-166.e13
33. Zhang Y, Thamer M, Stefanik K et al. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 2004; 44: 866-876
34. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590
35. Singh AK, Szczech L, Tang KL et al. (CHOIR Investigators). Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098
36. Drüeke TB, Locatelli F, Clyne N et al. (CREATE Investigators). Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084
37. Singh AK, Coyne DW, Shapiro W et al. (DRIVE Study Group). Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation. Kidney Int 2007; 71: 1163-1171
38. Kato A, Tsuji T, Luo J et al. Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients. Am J Nephrol 2008; 28: 115-121